SULCRATE SUSPENSION PLUS 1 G / 5 ML
SUCRALFATE : 1 G / 5 ML · DIN 02103567 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is SULCRATE SUSPENSION PLUS?
SULCRATE SUSPENSION PLUS 1 G / 5 ML contains SUCRALFATE : 1 G / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02103567, held by ABBVIE CORPORATION, supplied as SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Apr-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SULCRATE SUSPENSION PLUS used for?
Treatment of duodenal and non-malignant gastric ulcer; prophylaxis of duodenal ulcer recurrence and gastrointestinal hemorrhage due to stress ulceration in critically ill patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02103567 |
|---|---|
| Brand name | SULCRATE SUSPENSION PLUS |
| Generic / active ingredient | SUCRALFATE : 1 G / 5 ML |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 1 G / 5 ML |
| Dosage form | SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BX02 SUCRALFATE |
| AHFS class | 56:28.32 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Apr-2025 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Tablets: 1 g 4x/day (treatment) or 1 g 2x/day (prophylaxis). Suspension: 2 g 2x/day (duodenal ulcer) or 1 g 4-6x/day (stress ulcer prophylaxis). Administer on an empty stomach.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11 of full monograph).
How is it supplied?
Tablets: Bottles of 100. Suspension: Bottles of 500 mL.
Contraindications
Hypersensitivity to sucralfate or to any ingredient in the formulation.
Warnings and precautions
Do not administer IV (fatal complications). Risk of aluminum accumulation in renal failure. Bezoar formation reported. Hyperglycemia risk in diabetics (suspension). Caution in patients with dysphagia.
What can be used instead?
Other Canadian products sharing ATC code A02BX02 SUCRALFATE. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SUCRALFATE - TAB 1G | 1 G | TABLET | APOTEX INC | MARKETED | DIN 02125250 |
| SULCRATE | 1 G | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02100622 |
| TEVA-SUCRALFATE | 1 G | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02045702 |
| DOM-SUCRALFATE | 1000 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239912 |
| NU-SUCRALFATE - TAB 1GM | 1 G | TABLET | NU-PHARM INC | CANCELLED POST MARKET | DIN 02134829 |
| PMS-SUCRALFATE | 1 G | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02238209 |
| SUCRALFATE-1 - TAB 1G | 1 G | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02130939 |
| SULCRATE SUS 100MG/ML | 100 MG | SUSPENSION | LABS NORDIC LABORATORIES INC. - SUBSIDARY OF M.M.D.C. | CANCELLED POST MARKET | DIN 00836370 |
Who else supplies SUCRALFATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUCRALFATE appears in 14 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.